

Tecelra® (afamitresgene autoleucel) Prior Authorization Form

Member Name: _____ Date of Birth: _____ Member ID#: _____

Drug Information

Physician billing (HCPCS code: _____) Start Date (or date of next dose): _____

Dose: _____ Regimen: _____

Billing Provider Information

Provider NPI: _____ Provider Name: _____

Provider Phone: _____ Provider Fax: _____

Prescriber Information

Prescriber NPI: _____ Prescriber Name: _____

Prescriber Phone: _____ Prescriber Fax: _____ Specialty: _____

Criteria

For Authorization: (approvals will be for 1 dose per member per lifetime)

1. Please include the most recent office visit note or clinical summary from the hospital to support your request.
Is this information attached? Yes ___ No ___
2. Is the health care facility able to administer cellular therapies? Yes ___ No ___
3. Is the health care facility trained in the management of cytokine release syndrome (CRS) and neurologic toxicities? Yes ___ No ___
4. Please indicate the diagnosis and information:
 - Synovial Sarcoma**
 - A. Is disease unresectable or metastatic synovial sarcoma? Yes ___ No ___
 - B. Has the member received previous anthracycline or ifosfamide-containing chemotherapy?
Yes ___ No ___
 - C. Is member HLA-A*02:01P, -A*02:02P, A*02:03P, or -A*02:06P positive? Yes ___ No ___
 - D. Does tumor express melanoma-associated antigen A4 (MAGE-A4) as detected by an FDA-approved test? Yes ___ No ___
 - Other:** _____

Additional Information: _____

Prescriber Signature: _____ Date: _____

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge. Failure to complete this form in full will result in processing delays.

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy
Pharmacy Management Consultants
Product Based Prior Authorization Unit

Fax: 1-800-224-4014
Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.